Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C - a study of 527 patients at one establishment

2000 ◽  
Vol 7 (4) ◽  
pp. 268-275 ◽  
Author(s):  
Matsumura ◽  
Moriyama ◽  
Goto ◽  
Tanaka ◽  
Okubo ◽  
...  
2004 ◽  
Vol 43 (10) ◽  
pp. 902-910 ◽  
Author(s):  
Makoto ARIMA ◽  
Hideo TERAO ◽  
Kenji KASHIMA ◽  
Tsuyoshi ARITA ◽  
Masaru NASU ◽  
...  

Kanzo ◽  
1997 ◽  
Vol 38 (10) ◽  
pp. 587-595 ◽  
Author(s):  
Shunichi FUKUHARA ◽  
Kunihiko HINO ◽  
Koji KATO ◽  
Eiichi TOMITA ◽  
Shiro YUASA ◽  
...  

2016 ◽  
Vol 34 (6) ◽  
pp. 620-626 ◽  
Author(s):  
Satoru Hagiwara ◽  
Naoshi Nishida ◽  
Tomohiro Watanabe ◽  
Toshiharu Sakurai ◽  
Hiroshi Ida ◽  
...  

Objective: Treatment for chronic hepatitis C has recently developed in a very rapid manner. In Japan, in September 2014, IFN-free asunaprevir (ASV) and daclatasvir (DCV) became available for combination therapy. We report the treatment outcomes achieved at our hospital using this combination therapy. Methods: Sustained virological response (SVR) 24 could be evaluated in 120 of 125 patients with chronic liver disease type C who visited our hospital and were treated with ASV/DCV after September 2014, and these patients were analyzed. Results: SVR24 was achieved in 106 patients (88%). End-of-treatment response was not achieved in 10 patients (8.3%). Five of them carried multiple-resistant NS3/4A or NS5A region, and administration was discontinued early in 4 patients due to adverse effects. After ASV/DCV treatment, hepatocellular carcinoma (HCC) developed in 2 patients (1.7%) and recurred in 5 (4.2%). Conclusions: ASV/DCV treatment achieved favorable SVR in elderly and hepatic cirrhosis patients and patients in whom HCC was cured. However, an increase in the incidence of HCC development in patients who markedly respond to direct-acting antivirals treatment is expected and surveillance of HCC becomes more important.


2013 ◽  
Vol 51 (7-8) ◽  
pp. 564-574 ◽  
Author(s):  
Yuichiro Ikebuchi ◽  
Chihiro Ishida ◽  
Kinya Okamoto ◽  
Yoshikazu Murawaki

1992 ◽  
Vol 183 (3) ◽  
pp. 925-930 ◽  
Author(s):  
Eiji Mita ◽  
Norio Hayashi ◽  
Keiji Ueda ◽  
Akinori Kasahara ◽  
Hideyuki Fusamoto ◽  
...  

2021 ◽  
Author(s):  
Ola G Behairy ◽  
Soha A El‐Gendy ◽  
Dalia Y Ibrahim ◽  
Amira I Mansour ◽  
Ola S El‐Shimi

2021 ◽  
Vol 14 ◽  
pp. 175628482110234
Author(s):  
Mario Romero-Cristóbal ◽  
Ana Clemente-Sánchez ◽  
Patricia Piñeiro ◽  
Jamil Cedeño ◽  
Laura Rayón ◽  
...  

Background: Coronavirus disease (COVID-19) with acute respiratory distress syndrome is a life-threatening condition. A previous diagnosis of chronic liver disease is associated with poorer outcomes. Nevertheless, the impact of silent liver injury has not been investigated. We aimed to explore the association of pre-admission liver fibrosis indices with the prognosis of critically ill COVID-19 patients. Methods: The work presented was an observational study in 214 patients with COVID-19 consecutively admitted to the intensive care unit (ICU). Pre-admission liver fibrosis indices were calculated. In-hospital mortality and predictive factors were explored with Kaplan–Meier and Cox regression analysis. Results: The mean age was 59.58 (13.79) years; 16 patients (7.48%) had previously recognised chronic liver disease. Up to 78.84% of patients according to Forns, and 45.76% according to FIB-4, had more than minimal fibrosis. Fibrosis indices were higher in non-survivors [Forns: 6.04 (1.42) versus 4.99 (1.58), p < 0.001; FIB-4: 1.77 (1.17) versus 1.41 (0.91), p = 0.020)], but no differences were found in liver biochemistry parameters. Patients with any degree of fibrosis either by Forns or FIB-4 had a higher mortality, which increased according to the severity of fibrosis ( p < 0.05 for both indexes). Both Forns [HR 1.41 (1.11–1.81); p = 0.006] and FIB-4 [HR 1.31 (0.99–1.72); p = 0.051] were independently related to survival after adjusting for the Charlson comorbidity index, APACHE II, and ferritin. Conclusion: Unrecognised liver fibrosis, assessed by serological tests prior to admission, is independently associated with a higher risk of death in patients with severe COVID-19 admitted to the ICU.


Sign in / Sign up

Export Citation Format

Share Document